HanchorBio's Tri-Specific Therapy Offers New Hope for ‘Cold’ Tumors, Ignites Immuno-Oncology Race

San Diego, CA – November 8, 2025 – HanchorBio, a rapidly growing biotech firm, is generating significant buzz within the immuno-oncology field with promising preclinical data for its novel tri-specific antibody, HCB301. The therapy, designed to overcome the challenge of ‘cold’ tumors that resist traditional immunotherapy, is poised to potentially revolutionize cancer treatment and is attracting substantial investor interest.

For decades, immunotherapy has offered a beacon of hope for cancer patients, harnessing the power of the body’s own immune system to fight disease. However, many tumors, known as ‘cold’ tumors, lack the characteristics that allow the immune system to recognize and attack them. HanchorBio’s HCB301 aims to change that.

A Multi-Pronged Approach to Tumor Resistance

HCB301’s innovation lies in its tri-specific design. Unlike many existing immunotherapies that target a single immune checkpoint, HCB301 simultaneously blocks multiple pathways that tumors use to evade the immune system. According to preclinical data presented this week at the Society for Immunotherapy of Cancer (SITC) annual meeting, the therapy combines blockade of PD-1, a common immune checkpoint, with targeting of both CD47 – a ‘don’t eat me’ signal tumors use to hide from immune cells – and a key immunosuppressive signal within the tumor microenvironment.

“The simultaneous targeting of these multiple pathways is a game changer,” said one industry analyst familiar with the data, speaking on condition of anonymity. “Many companies are exploring bi-specific antibodies, but HCB301’s tri-specific approach appears to provide a more robust and comprehensive blockade of tumor immune evasion mechanisms.”

The FBDB™ Platform: A Flexible Foundation for Innovation

HanchorBio’s success is not solely attributable to HCB301. The company’s proprietary FBDB™ (Flexible Biologic Drug Builder) platform is enabling a rapid and efficient development of a diverse pipeline of immunotherapies. The platform’s modular design allows scientists to quickly and easily swap out different binding domains, creating antibodies with tailored specificity and functionality.

“The FBDB™ platform is a significant advantage,” notes Dr. Chen Ming, HanchorBio’s Chief Scientific Officer, in a recent interview. “It allows us to rapidly iterate on our designs and create antibodies that are precisely targeted to the unique characteristics of each tumor.”

According to company materials, the FBDB™ platform leverages advanced antibody engineering techniques and a proprietary cell line development process. This allows for the production of high-quality antibodies at scale.

The Competitive Landscape Heats Up

HanchorBio’s advancements come at a time when the immuno-oncology market is becoming increasingly competitive. Major pharmaceutical companies, including Gilead Sciences and Bristol Myers Squibb, are actively developing their own multi-specific antibodies and combination therapies.

Gilead Sciences is making significant strides with its own bi-specific antibodies targeting CD47 and PD-1, while Bristol Myers Squibb is pursuing a range of novel immunotherapies. However, HCB301’s tri-specific design, coupled with the versatility of the FBDB™ platform, appears to give HanchorBio a competitive edge.

“While there’s a lot of activity in this space, HCB301 stands out because of its comprehensive approach to overcoming tumor resistance,” explains a leading immuno-oncology researcher who reviewed the data, speaking on condition of anonymity. “The ability to simultaneously block multiple immune evasion mechanisms could translate into significantly improved clinical outcomes.”

Beyond HCB301: A Robust Pipeline

HCB301 is not HanchorBio’s only promising asset. The company is also developing HCB101, another immunotherapy targeting a different immune checkpoint, and a range of other pre-clinical programs. Clinical trials for HCB301 are currently recruiting patients with advanced solid tumors in both the United States and China, with preliminary data expected in late 2026.

Financial Backing Fuels Growth

HanchorBio’s rapid progress has attracted significant financial backing. The company recently closed a $150 million Series B funding round, led by a consortium of leading venture capital firms. This funding will enable HanchorBio to accelerate its clinical development programs and expand its research capabilities.

“The investors recognize the potential of our technology and our commitment to developing innovative immunotherapies,” said Dr. Li Wei, HanchorBio’s CEO. “We are committed to bringing these therapies to patients who desperately need them.”

The Road Ahead

While the preclinical data for HCB301 are promising, the journey from laboratory to clinic is fraught with challenges. Clinical trials will be crucial to determining the safety and efficacy of the therapy. However, if HCB301 proves successful, it could usher in a new era of immunotherapy, offering hope to patients with previously untreatable cancers.

The success of HanchorBio’s FBDB™ platform, coupled with the company’s focused approach to overcoming tumor resistance, positions it as a key player in the rapidly evolving immuno-oncology landscape. The coming years will be crucial in determining whether this innovative biotech firm can deliver on its promise and reshape the future of cancer treatment.